$POAI What Are Good Penny Stocks To Buy? 4 Biotech Stocks For Your List

Biotech stocks and penny stocks go hand-in-hand in many ways. One of the clearest is how speculation tends to drive momentum. Much like penny stocks, traders speculate on what potential outcomes may be during different phase trials that companies conduct. Furthermore, much like penny stocks, biotech stocks have a tendency to overreact on news days. This goes for both moves higher and lower.

This leads me to a big point, which is to pay attention to what companies discuss. That also goes for times when bad news hits. There may be short-term pain in lieu of a longer-term potential gain. It’s also important to consider that some biotech stocks will surge during the days leading up to a data date. They then can sell off once the news is released. Biotech stocks are well-known for the “buy the rumor, sell the news” type of trend. The name of the game here is to be on the right side of the move. Understanding all of these type of catalysts can help you make money with penny stocks, instead of holding a bag.

Now that the COVID headline has calmed down a bit, traders are now looking for more traditional biotech news. The long and short of it is that COVID may have introduced millions of new traders to the potential of biotech and now we’re seeing a fresh group of individuals interested in profiting from this volatile sector. Due to this, will any of these biotech penny stocks be on your list heading into December?

Biotech Stocks To Watch

1. Auris Medical Holding Ltd. (EARS Stock Report)
2. Predictive Oncology Inc. (POAI Stock Report)
3. Catabasis Pharmaceuticals (CATB Stock Report)
4. Mustang Bio Inc. (MBIO Stock Report)

Biotech Penny Stocks To Buy [or sell]: Auris Medical Holding Ltd.

Auris Medical Holding Ltd. is one of the biggest gainers of December 1st. During early trading on Tuesday, shares of EARS stock shot up by as much as 324%. In the past month, shares are up by almost 500%. So what is driving this massive bull run for EARS stock? Well, as a clinical-stage company working on therapeutics, Auris has been able to receive a critical appeal for meeting the needs of otherwise unmet areas of the healthcare sector.

On December 1st, the company announced that its substance AM-301, has shown a great deal of efficacy in protecting against Covid-19 infections. AM-301, which is a nasal spray, reduced viral titer by as much as 92.4% compared to a placebo.

“We are very excited to see the protective effects of AM-301 against Sars-CoV-2 confirmed in an assay that very closely replicates real-life conditions in the human nose. Our first experiments in September showed that AM-301s key component trapped up to 99% of Sars-CoV-2 when brought into contact with a viral suspension. Now, with our newly developed spray formulation, we have direct evidence that AM-301 has the potential to significantly mitigate the risk of infection of nasal mucosal cells.”

Thomas Meyer, the founder, and CEO of Auris

As a covid related penny stock, Auris Medical Holdings looks like it could have a lot of potentials if things continue to go well for it. With this in mind, Auris Medical could remain a penny stock to watch for the near term.

Biotech Penny Stocks To Buy [or sell]: Predictive Oncology Inc.

Predictive Oncology Inc. has begun building some momentum during the last few weeks. Most recently, POAI stock has jumped a bit more after reporting a strong, year-over-year EPS growth. In its previous Q3 2019 report, EPS came in at a loss per share of $1.31. This year, the loss was 46 cents per share. While sales were lower, year over year, the company’s discussion on upcoming milestones and current initiatives seems ot have sparked renewed interest.

“Management continues to focus the majority of its resources on the Company’s primary mission of applying artificial intelligence to precision medicine and to drug discovery. Our approach and the mediums used to replace rats and mice in preliminary cancer studies are working in three of our operating subsidiaries, Helomics, TumorGenesis and Soluble Biotech.”

Dr. Carl Schwartz, Predictive Oncology CEO

Right now traders are monitoring the company for its expected completion of a Helomics Magee study. Helomics applies artificial intelligence to its rich data gathered from patient tumors to personalize cancer therapies for patients and drive the development of new targeted therapies.

Biotech Penny Stocks To Buy [or sell]: Catabasis Pharmaceuticals

Catabasis Pharmaceuticals is another one of the penny stocks that has been climbing for the last month or so. After dropping from levels above $6 in October, CATB stock has followed a slow and steady uptrend from $1.25 to recent highs of $1.75 this month.

Read More

• 3 Penny Stocks On Robinhood To Buy For Under $1 In December
• 4 Penny Stocks to Watch For Early December 2020

As I said above, it’s about what managed says after both good and bad results. In this case, Catabasis reported that its Phase 3 PolarisDMD trial of its edasalonexent treatment for Duchenne muscular dystrophy missed its primary endpoint. As a result, the comapny said it was stopping activities related to the development of edasalonexent. Catabasis’ plan was to work with advisors to evaluate alternatives. The company engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor.

“Potential strategic options that may be evaluated include a merger, business combination, in-licensing, out-licensing or other strategic transaction.”

As we saw earlier this week with certain companies taking up a similar platform, though it took time, many ended up coming out stronger. Will that be the case for Catabasis?

Biotech Penny Stocks To Buy [or sell]: Mustang Bio Inc.

Mustang Bio Inc. has been a force to reckon with during the month of November and now into December. Since November 2nd, MBIO stock has climbed from around $2.70 to highs this week of $3.85. A lot of that momentum stemmed from strong earnings as well as new agreements. There was also an apparent speculative build-up to the company’s upcoming key opinion leader call later this month.

First, the company and Minaris Regenerative Medicine GmbH announced an agreement to enable technology transfer and GMP clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program. This is for the treatment of X-linked severe combined immunodeficiency also known as bubble boy disease, in Europe. Minaris is a leading contract development and manufacturing service provider for the cell and gene therapy industry.

Following this, Mustang received a long-awaited opinion from the European Medicines Agency on the Orphan Drug Designation of lentriviral for bubble boy disease. The Designation applies to MB-107 for the treatment of newly diagnosed infants between two months and two years of age. It also applies to to MB-207 for the treatment of patients who have been previously treated with hematopoietic stem cell transplantation and for whom re-treatment is indicated.

This week interim Phase 1/2 data on Mustang Bio’s MB-106, a CAR-T cell therapy for patients with certain non-Hodgkin lymphomas, will be presented at the ASH meeting.